Sanara Ventures

Sanara Ventures is a seed-stage technological incubator based in Ra’anana, Israel, backed by Teva and Philips, writing checks of $250K to $1M at pre-seed and seed. The firm provides 360-degree regulatory and clinical support for nascent medtech and bio-convergence startups, drawing on the deep operating experience of its corporate backers in pharmaceuticals and medical devices. Founders engaging with Sanara are working with a structure designed for founders who need substantial guidance through early company formation and regulatory groundwork.

The thesis covers medical devices and medtech and digital health, with particular emphasis on bio-convergence companies combining biological, digital, and engineering disciplines. Sanara is interested in early-stage companies that benefit from the strategic engagement of Teva and Philips, including access to clinical, regulatory, and commercial expertise that few seed investors can match. The portfolio reflects a willingness to support companies with long technical and regulatory development paths, provided the underlying science and team are credible.

Check sizes of $250K to $1M place Sanara as an early-stage incubator investor, often participating in pre-seed and seed rounds and providing substantial non-financial support alongside the capital. The geographic focus is Israel, with portfolio companies generally building toward global markets. Founders should expect a long-engagement incubator model rather than a passive check, with hands-on support during company formation, regulatory strategy, clinical validation, and early commercialization planning. The corporate backing from Teva and Philips shapes the kinds of companies that fit and the kind of support available.

The team includes investors and operators with backgrounds spanning pharmaceuticals, medical devices, regulatory affairs, and Israeli technology venture, working closely with the operating teams at Teva and Philips. That structure gives portfolio companies access to advisors who can engage on the specifics of pharmaceutical product development, medical device regulation, and global healthcare commercialization, which is unusually deep for a seed-stage investor.

Sanara Ventures’ working style is hands-on and operationally engaged. The firm typically takes board seats and engages closely on regulatory strategy, clinical development, and commercial planning, with the additional benefit of strategic engagement from Teva and Philips when there is alignment. Sanara co-invests with Israeli and international healthcare-focused VCs and has supported portfolio companies through subsequent rounds and strategic partnerships. Founders building medtech, bio-convergence, or digital health companies in Israel that benefit from deep regulatory and clinical support at the earliest stages, and who want corporate strategic engagement built into the relationship from day one, will find Sanara well-suited to that path. Founders looking for a passive check or a fast-cycle software investor should look elsewhere.